Article Data

  • Views 372
  • Dowloads 147

Original Research

Open Access

Uterine serous carcinoma: a historic evaluation of therapy

  • F.A. de Leeuw1,*,
  • F.E.M. Rijcken1
  • J.W. Trum2
  • V. van der Noort3
  • R.I. Tjon-Kon-Fat1
  • M.C.G. Bleeker2
  • G.G. Kenter1

1Department of Gynecology, Center for Gynecologic Oncology, Amsterdam, The Netherlands

2Department of Pathology, VU University Medical Center and Academic Medical Center, Amsterdam, The Netherlands

3Department of Biometrics, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands

DOI: 10.12892/ejgo3153.2016 Vol.37,Issue 2,April 2016 pp.211-215

Published: 10 April 2016

*Corresponding Author(s): F.A. de Leeuw E-mail:


Objective: Uterine serous carcinoma (USC) is an aggressive, histological subtype of endometrial cancer with a poor prognosis. This study evaluates the additional effect of staging surgery above total abdominal hysterectomy and bilateral salpingo-oophorectomy (TAH + BSO) on the use of adjuvant therapy and subsequent survival outcomes in clinical early-stage USC patients. Materials and Methods: This retrospective cohort study includes 75 women treated for clinical early-stage USC. Results: In 33 (44%) clinical early-stage patients surgical staging was performed and 15 patients (45%) proved to have lymphatic or abdominal metastasis. Use of adjuvant therapy was similar in patients, both staged with no metastasis (n = 18) and patients who underwent TAH and BSO only (n = 42, p = 0.17). No significant survival difference was found between surgically staged and TAH + BSO patients. Conclusions: Surgical staging proved to be important to determine stage of disease and hence prognosis. Surgical staging did not lead to selective avoidance of adjuvant therapy in patients with no metastasis.


Uterine serous carcinoma; Surgical staging; TAH; BSO.

Cite and Share

F.A. de Leeuw,F.E.M. Rijcken,J.W. Trum,V. van der Noort,R.I. Tjon-Kon-Fat,M.C.G. Bleeker,G.G. Kenter. Uterine serous carcinoma: a historic evaluation of therapy. European Journal of Gynaecological Oncology. 2016. 37(2);211-215.


[1] Amant F., Moerman P., Neven P., Timmerman D., Van L.E., Vergote I.: “Treatment modalities in endometrial cancer”. Curr. Opin. Oncol., 2007, 19, 479.

[2] Boruta D.M., Gehrig P.A., Fader A.N., Olawaiye A.B.: “Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review”. Gynecol. Oncol., 2009, 115, 142.

[3] Jemal A., Siegel R., Xu J., Ward E.: “Cancer statistics, 2010”. CA Cancer J Clin., 2010, 60, 277.

[4] Ferlay J., Parkin D.M.: “Steliarova-Foucher E. “Estimates of cancer incidence and mortality in Europe in 2008”. Eur. J. Cancer, 2010, 46, 765.

[5] Hamilton C.A., Cheung M.K., Osann K., Chen L., Teng N.N., Longacre T.A., et al.: “Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers”. Br. J. Cancer, 2006, 94, 642.

[6] “Dutch guidelines of uterine carcinoma”. Netherlands, cited March 9, 2015. Available at:

[7] Moore K.N., Fader A.N.: “Uterine papillary serous carcinoma”. Clin. Obstet. Gynecol., 2011, 54, 278.

[8] Geisler J.P., Geisler H.E., Melton M.E., Wiemann M.C.: “What staging surgery should be performed on patients with uterine papillary serous carcinoma?” Gynecol. Oncol., 1999, 74, 465.

[9] Chan J.K., Loizzi V., Youssef M., Osann K., Rutgers J., Vasilev S.A. et al.: “Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium”. Gynecol. Oncol., 2003, 90, 181.

[10] Viswanathan A.N., Macklin E.A., Berkowitz R., Matulonis U.: “The importance of chemotherapy and radiation in uterine papillary serous carcinoma”. Gynecol. Oncol., 2011, 123, 542.

[11] Kelly M.G., O'malley D.M., Hui P., McAlpine J., Yu H., Rutherford

T. J., et al.: “Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy”. Gynecol. Oncol., 2005, 98, 353

[12] Goldberg H., Miller R.C., Abdah-Bortnyak R., Steiner M., Yildiz F., Meirovitz A., et al.: “Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN)”. Gynecol. Oncol., 2008, 108, 298.

[13] Fader A.N., Drake R.D., O'malley D.M., Gibbons H.E., Huh W.K., Havrilesky L.J., et al.: “Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma”. Cancer, 2009, 115, 2119.

[14] Keys H.M., Roberts J.A., Brunetto V.L., Zaino R.J., Spirtos N.M., Bloss J.D., et al.: “A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study”. Gynecol. Oncol., 2004, 92, 744.

[15] Creutzberg C.L., van Putten W.L., Koper P.C., Lybeert M.L., Jobsen J.J., Warlam-Rodenhuis C.C., et al.: “Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma”. Lancet, 2000, 355, 1404.

[16] Aalders J., Abeler V., Kolstad P., Onsrud M.: “Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: clinical and histopathologic study of 540 patients”. Obstet. Gynecol., 1980, 56, 419.

[17] Ayeni T.A., Bakkum-Gamez J.N., Mariani A., McGree M.E., Weaver A. L., Haddock M.G., et al.: “Comparative outcomes assessment of uterine grade 3 endometrioid, serous, and clear cell carcinomas”. Gynecol. Oncol., 2013, 129, 478.

[18] Lee L.J., Demaria R., Berkowitz R., Matulonis U., Viswanathan A.N.: “Clinical predictors of long-term survival for stage IVB uterine papillary serous carcinoma confined to the abdomen”. Gynecol. Oncol., 2014, 132, 65.

[19] Lauchlan S.C.: “Tubal (serous) carcinoma of the endometrium”. Arch. Pathol. Lab. Med., 1981, 105, 615.

[20] Hendrickson M., Ross J., Eifel P., Martinez A., Kempson R.: “Uterine papillary serous carcinoma: a highly malignant form of endometrial adenocarcinoma”. Am. J. Surg. Pathol., 1982, 6, 93.

[21] Gehrig P.A.: “Uterine papillary serous carcinoma: a review”. Expert Opin. Pharmacother., 2007, 8, 809.

[22] R Core Team (2012): “R: A language and environment for statistical computing”. R Foundation for Statistical Computing, Vienna, Austria. Available at:

[23] Odicino F.E., Bignotti E., Rossi E., Pasinetti B., Tassi R.A., Donzelli C., et al.: “HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization”. Int. J. Gynecol. Cancer, 2008, 18, 14.

[24] Wilson T.O., Podratz K.C., Gaffey T.A., Malkasian G.D., Jr., O'Brien P. C., Naessens J.M.: “Evaluation of unfavorable histologic subtypes in endometrial adenocarcinoma”. Am. J. Obstet. Gynecol., 1990, 162, 418.

[25] Zheng W., Cao P., Zheng M., Kramer E.E., Godwin T.A.: “p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes”. Gynecol. Oncol., 1996, 61, 167.

[26] Chambers J.T., Merino M., Kohorn E.I., Peschel R.E., Schwartz P.E.: “Uterine papillary serous carcinoma”. Obstet. Gynecol., 1987, 69, 109

[27] Cirisano F.D., Jr., Robboy S.J., Dodge R.K., Bentley R.C., Krigman H. R., Synan I.S., et al.: “Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma”. Gynecol. Oncol., 1999, 74, 385.

[28] Hogberg T., Signorelli M., de Oliveira C.F., Fossati R., Lissoni A.A., Sorbe B., et al.: “Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer--results from two randomised studies”. Eur. J. Cancer, 2010, 46, 2422.

[29] Hogberg T., Rosenberg P., Kristensen G., de Oliveira C.F., de Pont Christensen R., Sorbeet B., et al.: “A randomized phase-III study on adjuvant treatment with radiation (RT) +/- chemotherapy (CT) in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991)”. J. Clin. Oncol., 2007, 25, 5503.

[30] “Portec 3 trial”. Netherlands and United Kingdom, cited March 9, 2015. Available at:

[31] Turner B.C., Knisely J.P., Kacinski B.M., Haffty B.G., Gumbs A. A., Roberts K.B., et al.: “Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy”. Int. J. Radiat. Oncol. Biol. Phys., 1998, 40, 77.

[32] “Gynecologic Cancer InterGroup (GCIG)”. Cited March 9, 2015. Available at: Statec_GCIG_171113.pdf

Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time